PE20220401A1 - Proteinas de fusion terapeuticas - Google Patents

Proteinas de fusion terapeuticas

Info

Publication number
PE20220401A1
PE20220401A1 PE2022000365A PE2022000365A PE20220401A1 PE 20220401 A1 PE20220401 A1 PE 20220401A1 PE 2022000365 A PE2022000365 A PE 2022000365A PE 2022000365 A PE2022000365 A PE 2022000365A PE 20220401 A1 PE20220401 A1 PE 20220401A1
Authority
PE
Peru
Prior art keywords
fusion proteins
acute
therapeutic fusion
organ
tissue
Prior art date
Application number
PE2022000365A
Other languages
English (en)
Inventor
Sebastien Irigaray
Laurent Klein
Darko Skegro
Marco Villani
Karl Welzenbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67875416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20220401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20220401A1 publication Critical patent/PE20220401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Signal Processing (AREA)

Abstract

La presente invencion se refiere a proteinas de fusion adecuadas para su uso como medicamento o herramienta de investigacion. Los usos terapeuticos de las proteinas de fusion pueden incluir la prevencion o el tratamiento de trastornos inflamatorios agudos o cronicos y microvasculares y de organos impulsados por el sistema inmunitario, por ejemplo, lesion renal aguda, sindrome de dificultad respiratoria aguda, sepsis, infarto agudo de miocardio, fibrosis tisular y otras lesiones de organos resultantes del trauma tisular.
PE2022000365A 2019-09-06 2020-09-04 Proteinas de fusion terapeuticas PE20220401A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19196045 2019-09-06
PCT/IB2020/058250 WO2021044360A1 (en) 2019-09-06 2020-09-04 Therapeutic fusion proteins

Publications (1)

Publication Number Publication Date
PE20220401A1 true PE20220401A1 (es) 2022-03-22

Family

ID=67875416

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022000372A PE20221051A1 (es) 2019-09-06 2020-09-04 Proteinas de fusion terapeuticas
PE2022000365A PE20220401A1 (es) 2019-09-06 2020-09-04 Proteinas de fusion terapeuticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2022000372A PE20221051A1 (es) 2019-09-06 2020-09-04 Proteinas de fusion terapeuticas

Country Status (22)

Country Link
US (3) US20230220048A1 (es)
EP (3) EP4025238A1 (es)
JP (4) JP7671739B2 (es)
KR (3) KR20220058586A (es)
CN (8) CN119285791A (es)
AR (2) AR119902A1 (es)
AU (3) AU2020343512A1 (es)
BR (2) BR112022003762A2 (es)
CA (3) CA3152990A1 (es)
CO (2) CO2022002567A2 (es)
CR (2) CR20220089A (es)
CU (2) CU20220016A7 (es)
EC (2) ECSP22016180A (es)
IL (3) IL290618A (es)
JO (2) JOP20220055A1 (es)
MX (2) MX2022002638A (es)
MY (1) MY208682A (es)
PE (2) PE20221051A1 (es)
PH (2) PH12022550539A1 (es)
TW (2) TW202122414A (es)
WO (3) WO2021044360A1 (es)
ZA (2) ZA202201827B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7659499B2 (ja) * 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
EP4326307A4 (en) * 2021-04-22 2025-03-05 Biolegend, Inc. PHOSPHATIDYLSERINE BINDING AGENT FOR THE DETECTION AND DEGRADATION OF PHOSPHATIDYLSERINE-POSITIVE CELLS
KR102801198B1 (ko) * 2021-06-28 2025-04-30 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 폴리펩타이드 및 이를 포함하는 약학 조성물
CN114288386B (zh) * 2022-01-25 2023-12-12 华中科技大学同济医学院附属协和医院 Del-1作为炎症性肠病新的生物标志物及治疗药物应用
TW202417520A (zh) * 2022-10-14 2024-05-01 南韓商伊米斯療法股份有限公司 融合分子和治療免疫性疾病的方法
WO2025086968A1 (zh) * 2023-10-25 2025-05-01 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物
CN121100135A (zh) * 2024-04-18 2025-12-09 苏州鲲石一号生物科技有限公司 Gas6融合蛋白及其制备方法与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
AU2006243905B2 (en) 2005-05-13 2011-09-01 The Feinstein Institute For Medical Research Milk fat globule epidermal growth factor-factor VIII and sepsis
CN101511866A (zh) * 2006-09-08 2009-08-19 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CA2705541C (en) 2007-11-15 2018-09-11 The Feinstein Institute For Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
JP2013519392A (ja) 2010-02-16 2013-05-30 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
JP6161541B2 (ja) * 2011-02-03 2017-07-12 ゾーマ テクノロジー リミテッド 細菌中の機能的タンパク質発現を向上させるための方法および物質
CA2826683A1 (en) 2011-02-15 2012-08-23 Medimmune, Llc Hsa-related compositions and methods of use
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
US20140121163A1 (en) 2011-04-28 2014-05-01 The Feinstein Institute for Medical Research a corporation Mfg-e8 and uses thereof
MX353816B (es) 2011-05-05 2018-01-30 Albumedix As Variantes de albumina.
US20140302027A1 (en) * 2011-09-26 2014-10-09 University Of Louisville Research Foundation, Inc. Methods of treating periodontal inflammation and periodontal bone loss
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
EP3037534B1 (en) 2013-08-23 2021-02-17 Riken Polypeptide exhibiting fluorescent properties, and utilization of same
UA130573C2 (uk) * 2014-03-31 2026-03-25 Ханмі Фарм. Ко., Лтд. Спосіб покращення розчинності білка та пептиду із застосуванням зв'язування з fc-фрагментом імуноглобуліну
CN106537795B (zh) * 2014-03-31 2021-10-01 英国电讯有限公司 数据通信
US20170136089A1 (en) * 2014-05-15 2017-05-18 The Trustees Of The University Of Pennsylvania Compositions and methods of regulating bone resorption
KR20170013621A (ko) 2015-07-28 2017-02-07 (주) 넥셀 Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물
CA3000742A1 (en) * 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
CN110382529B (zh) * 2017-03-02 2024-03-08 诺华股份有限公司 工程化的异源二聚体蛋白质
KR101947902B1 (ko) 2017-05-17 2019-02-13 (주) 넥셀 간 섬유화 예방 또는 치료용 재조합 단백질 및 이를 포함하는 간 섬유화 예방 또는 치료용 조성물
JP7659499B2 (ja) 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法

Also Published As

Publication number Publication date
TW202122414A (zh) 2021-06-16
TWI873177B (zh) 2025-02-21
ZA202201828B (en) 2023-10-25
JP2025124629A (ja) 2025-08-26
KR20220058585A (ko) 2022-05-09
ZA202201827B (en) 2023-11-29
WO2021044362A1 (en) 2021-03-11
PE20221051A1 (es) 2022-06-30
PH12022550539A1 (en) 2023-03-20
CR20220089A (es) 2022-03-30
CR20220096A (es) 2022-05-11
CN118772293A (zh) 2024-10-15
US20230220048A1 (en) 2023-07-13
KR20220058588A (ko) 2022-05-09
CA3152500A1 (en) 2021-03-11
ECSP22016558A (es) 2022-04-29
CN114302896A (zh) 2022-04-08
IL290618A (en) 2022-04-01
TW202122415A (zh) 2021-06-16
JP2022547111A (ja) 2022-11-10
JP7808547B2 (ja) 2026-01-29
US20230308835A1 (en) 2023-09-28
CN118667031A (zh) 2024-09-20
AU2020340618A1 (en) 2022-04-07
AR119902A1 (es) 2022-01-19
US20230265160A1 (en) 2023-08-24
MY208682A (en) 2025-05-23
MX2022002637A (es) 2022-03-25
EP4025238A1 (en) 2022-07-13
BR112022003762A2 (pt) 2022-05-31
WO2021044361A1 (en) 2021-03-11
CA3152990A1 (en) 2021-03-11
AU2020343512A1 (en) 2022-04-07
JP2022547051A (ja) 2022-11-10
CN114341194A (zh) 2022-04-12
AR119905A1 (es) 2022-01-19
CN118812727A (zh) 2024-10-22
WO2021044360A1 (en) 2021-03-11
JOP20220055A1 (ar) 2022-03-02
BR112022003745A2 (pt) 2022-05-31
CO2022002545A2 (es) 2022-04-08
AU2020343926A1 (en) 2022-04-07
CO2022002567A2 (es) 2022-04-08
IL290660A (en) 2022-04-01
JP2022547050A (ja) 2022-11-10
IL290675A (en) 2022-04-01
JOP20220058A1 (ar) 2023-01-30
CU20220015A7 (es) 2022-10-11
AU2020343926B2 (en) 2024-11-21
CA3152499A1 (en) 2021-03-11
CN119285791A (zh) 2025-01-10
PH12022550538A1 (en) 2023-03-20
JP7671739B2 (ja) 2025-05-02
CN114341195A (zh) 2022-04-12
JP7834637B2 (ja) 2026-03-24
AU2020340618B2 (en) 2025-01-23
KR20220058586A (ko) 2022-05-09
EP4025237A1 (en) 2022-07-13
ECSP22016180A (es) 2022-04-29
MX2022002638A (es) 2022-03-25
CU20220016A7 (es) 2022-10-11
CN118909136A (zh) 2024-11-08
CN114341195B (zh) 2025-04-25
EP4025239A1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
CO2022002545A2 (es) Proteínas de fusión terapéuticas
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
BR112021025964A2 (pt) Formas de sal de ácido bempedoico e métodos para uso das mesmas
EP4342540A3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
MX390535B (es) Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
CO2022007953A2 (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
CL2012000092A1 (es) Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias.
CL2018000835A1 (es) Prevención, tratamiento y reversión de la enfermedad usando una cantidad terapeuticamente efectiva de ácidos grasos activados
GT200500316A (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
MX2022003585A (es) Metodos para tratar hiperfenilalaninemia.
MX2019004484A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
CR20210021A (es) Apirasas solubilizadas, métodos y usos
PE20210123A1 (es) Compuesto de anillo de metillactama y uso farmaceutico del mismo
PE20170524A1 (es) Dihidropirimidinonas biciclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofila
MX2019008961A (es) Composicion intranasal que comprende betahistina.
BR112018068960A2 (pt) formulações de enalapril
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
MX2023008567A (es) Acidos monocarboxilicos y dicarboxilicos de hidrocarburos de cadena larga funcionalizados y derivados de estos, y su uso para la prevencion o el tratamiento de enfermedades.
EA201990947A1 (ru) Замещенные производные 6-(1h-пиразол-1-ил)пиримидин-4-амина и их применение
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel